Ionis Pharmaceuticals Inc

Most Recent

  • uploads///Chart
    Earnings Report

    A Look at Ionis’s Revenue Streams in the Second Quarter

    Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to the revenues of $112 million during the second quarter of 2017.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    Why Alnylam Pharmaceuticals Stock Rose ~16% Yesterday

    Yesterday, Alnylam Pharmaceuticals (ALNY) closed the day ~16.3% higher than the previous day’s closing price.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    What Analysts Think about Ionis

    In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Ligand Pharmaceuticals Focuses on Increasing Returns for Shareholders

    Ligand Pharmaceuticals has developed a product portfolio that spans more than 700 patents offering varying degrees of protection to the assets.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Alnylam Pharmaceuticals: Developing Therapies for Hereditary ATTR Amyloidosis

    Alnylam Pharmaceuticals (ALNY) is currently developing three investigational therapies—Patisiran, Revusiran, and ALN-TTRsc02—for the treatment of patients with hereditary ATTR amyloidosis.

    By Margaret Patrick
  • uploads///attractive product profile
    Company & Industry Overviews

    What’s behind Biogen Buyout Rumors?

    Since early August 2016, there have been rumors of a likely buyout of Biogen (BIIB) by one of the many interested suitors in the biotechnology industry.

    By Sarah Collins
  • uploads///Graph
    Earnings Report

    What Do Analysts Recommend for United Therapeutics?

    23.1% of analysts gave United Therapeutics (UTHR) a “buy” recommendation while 69.2% of analysts rated the company a “hold.”

    By Margaret Patrick
  • uploads///close up drugs medical medicine
    Company & Industry Overviews

    Wall Street Is Bullish on Nektar Stock despite Stock Price Slump

    Nektar is a development-stage biotechnology company that has a drug pipeline focused on the treatment of cancer, autoimmune diseases, and chronic pain.

    By Sarah Collins
  • uploads///Spectrum
    Company & Industry Overviews

    A Look at Spectrum’s Financial Position in September

    In the second quarter, Spectrum Pharmaceuticals (SPPI) generated net revenues of $24.2 million compared to $34.3 million in Q2 2017.

    By Daniel Collins
  • uploads///Spectrum net loss
    Company & Industry Overviews

    Spectrum Pharmaceuticals: Earnings Trends and Recent Developments

    In the first nine months of 2018, Spectrum Pharmaceuticals reported a net income and diluted EPS of -$70.8 million and -$0.69, respectively.

    By Daniel Collins
  • uploads///IONS
    Company & Industry Overviews

    Do Analysts See Any Upside for Ionis Stock?

    Of the 14 analysts covering Ionis Pharmaceuticals (IONS), five have given it “buy” or higher ratings, seven have given it “holds.”

    By Kenneth Smith
  • uploads///molecule _
    Company & Industry Overviews

    Taking Stock of Ionis’s Performance

    Ionis Pharmaceuticals’ (IONS) two business segments are Ionis Core and Akcea Therapeutics, in which Ionis holds a 76% stake.

    By Kenneth Smith
  • uploads///Chart
    Earnings Report

    Amgen: Analysts’ Recommendations on October 25

    Wall Street analysts expect Amgen’s (AMGN) revenues to decrease marginally by ~0.1% to $5.769 billion during the third quarter.

    By Mike Benson
  • uploads///blood _
    Earnings Report

    Alkermes in the Third Quarter: A Performance Overview

    Alkermes (ALKS) reported its third-quarter results on October 23. It generated net revenues of $248.7 million, a 14% YoY growth.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Biogen: Revenue Growth Is Expected in Q3

    Interferon contributed ~18% of Biogen’s total revenues. Analysts expect the revenues to decrease during the third quarter.

    By Mike Benson
  • uploads///IONS
    Company & Industry Overviews

    A Financial Overview of Ionis Pharmaceuticals in October

    Ionis Pharmaceuticals generated Q2 2018 revenues of $118.0 million compared to $122.3 million in Q2 2017, which reflected ~15.0% YoY growth.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Revenue Stream

    Ionis’s Commercial Revenues segment reported second-quarter revenues of $57.0 million, compared to $24.0 million during the second quarter of 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Revenue Growth Rate

    Ionis Pharmaceuticals (IONS) reported revenues of $262.0 million during the first half of 2018.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Valuations on September 28

    Ionis reported revenues of $118.0 million during the second quarter for 5.0% growth in year-over-year revenues compared to the second quarter of 2017.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Stock Performance in September

    On September 28, Ionis Pharmaceuticals received one “strong buy” rating, three “buy” ratings, seven “hold” ratings, and two “sell” ratings.

    By Mike Benson
  • uploads///laboratory _
    Company & Industry Overviews

    A Look at Incyte’s Valuation on August 22

    On August 22, Incyte was trading at a forward price-to-earnings multiple of 38.1x compared to the industry average of ~13.9x.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What Analysts Recommend for Ionis after Q2 2018

    Wall Street analysts estimate Ionis Pharmaceuticals (IONS) will report year-over-year growth of ~34.8% in revenues to $612.5 million in 2018 as compared to revenues of $507.7 million during 2017.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?

    Ionis Pharmaceuticals (IONS), a leading RNA-targeted therapeutics developing company, aims to develop best-in-class drugs for life-threatening diseases.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    How Ionis’s Q2 2018 Earnings Trended

    Ionis reported 5% YoY growth in revenues to $117.7 million during Q2 2018 as compared to $112.3 million during the second quarter of 2017.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analysts Have Mixed Opinions about Ionis

    Wall Street analysts estimate that Ionis’s (IONS) Q2 2018 revenues will rise ~30.0% to $135.5 million as compared to $104.2 million in Q2 2017.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    What Do Analysts Expect from Ionis’s Q2 2018 Earnings?

    Ionis is expected to report 30.0% growth in revenues to $135.5 million in the second quarter of 2018 as compared to $104.2 million in Q2 2017.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    Bluebird Bio Misses Analysts’ Estimates in Q2 2018

    Clinical-stage biotechnology company Bluebird Bio (BLUE) released its Q2 2018 results yesterday, missing analysts’ revenue and EPS estimates.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Sage Therapeutics’ GABA Receptor–Based Products

    On June 12, Sage Therapeutics announced its expedited development plan for SAGE-217.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    How Ionis Pharmaceuticals’ Valuation Compares

    Ionis Pharmaceuticals (IONS), a therapeutics development leader, commercializes products in collaboration with other pharmaceutical companies.

    By Mike Benson
  • uploads///Firefish
    Company & Industry Overviews

    Risdiplam: Could It Be PTC Therapeutics’ Future Growth Driver?

    In June, PTC Therapeutics (PTCT) presented its updated interim clinical data from the Phase 1 FIREFISH trial.

    By Daniel Collins
  • uploads///dna _
    Company & Industry Overviews

    Biogen and Ionis Crash on PTC Therapeutics’ Promising Data

    Yesterday, PTC Therapeutics (PTCT) registered a stock price rise of ~24.6% on the positive data the company presented along with partner Roche (RHHBY) for their SMA (spinal muscular atrophy) drug risdiplam.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    Key Updates on Akcea Therapeutics’ Volanesorsen

    Ionis Pharmaceuticals’ (IONS) Volanesorsen is a drug for the treatment of familial chylomicronemia syndrome (or FCS) and familial partial lipodystrophy (or FPL).

    By Mike Benson
  • uploads///AKCA
    Company & Industry Overviews

    Exploring the Financial Performance of Akcea Therapeutics

    In 2017, Akcea Therapeutics (AKCA) generated total revenue of $55.2 million.

    By Kenneth Smith
  • uploads///syringe _
    Company & Industry Overviews

    Analysts’ Recommendations for Akcea and Its Peers in March

    Akcea Therapeutics is currently advancing a mature pipeline of four novel drugs with the potential to treat many cardiometabolic diseases.

    By Kenneth Smith
  • uploads///Spinraza
    Company & Industry Overviews

    How Biogen’s Spinraza Is Positioned for 2018

    In 4Q17, Biogen’s (BIIB) Spinraza generated revenues of $363 million, which reflected 34% quarter-over-quarter growth.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Developments for Ionis Pharmaceuticals Post-3Q17

    Ionis Pharmaceuticals (IONS) is focused on the development of drugs for the treatment of diseases with limited or nontherapeutic options.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at Ionis’s 3Q17 Revenue Stream

    Ionis Pharmaceuticals (IONS) reported a 9% rise in its revenue to $120.9 million in 3Q17 compared to $110.9 million in 3Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Exploring Ionis’s 3Q17 Quarterly Revenue Trend

    Ionis’s revenue sources include its commercial revenue and its research and development revenue under its collaborative agreements.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at Ionis Pharmaceuticals’ January 2018 Valuation

    On January 5, Ionis Pharmaceuticals’ stock value had risen ~4.3% over the last 12 months. Analysts expect the stock to rise ~14.0% over the next 12 months.

    By Mike Benson
  • uploads///Jazz analyst
    Company & Industry Overviews

    How Analysts Rated Jazz Pharmaceuticals in December

    In December 2017, Jazz Pharmaceuticals (JAZZ) submitted a New Drug Application (or NDA) to the FDA for the approval of JZP-110.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Givosiran May Become Major Growth Driver for Alnylam Pharmaceuticals

    On September 7, 2017, Alnylam Pharmaceuticals (ALNY) announced that it had reached an agreement with the US Food and Drug Administration (or FDA) related to the design of the phase three program for investigational RNAi therapeutic Givosiran.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Alnylam Is Preparing for Commercial Launch of Patisiran

    To ensure the smooth commercial launch of investigational RNAi therapy Patisiran, Alnylam Pharmaceuticals (ALNY) has been actively involved in building its manufacturing, quality, and distribution infrastructure in the US and Europe.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Patisiran Expected to Become Key Growth Driver for Alnylam

    Alnylam Pharmaceuticals’ (ALNY) investigational drug Patisiran is expected to target 20,000 to 30,000 patients with hereditary ATTR (or hATTR) Amyloidosis with polyneuropathy caused by amyloid deposition in nerves.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Recommend for Alnylam Pharmaceuticals and Peers

    On September 20, 2017, Alnylam Pharmaceuticals (ALNY) announced positive top-line results from phase three trial APOLLO.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Geographic Market Expansion to Boost Spinraza Sales in 2017

    In 3Q17, Biogen (BIIB) and Ionis Pharmaceuticals’ (IONS) Spinraza reported sales worth $73 million from international markets.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Technology Platforms and Research Programs Drive LGND’s Partnerships

    Ligand Pharmaceuticals (LGND) has entered multiple fully funded partnerships by licensing its technology platforms such as OmniAb, Captisol, LTP Technology, and SUREtechnology Platform.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Fully Funded Partnerships May Drive Growth for Ligand Pharmaceuticals

    Ligand Pharmaceuticals (LGND) expects its licensees to invest ~$2.0 billion for advancing more than 155 partnered research and development programs in 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Ligand Pharmaceuticals’ Shots-on-Goal Business Model

    Ligand Pharmaceuticals (LGND) has developed a business model called Shots-on-Goal, which is based on fully funded partnerships.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Must-Know Developments for Ionis Pharmaceuticals

    Ionis entered a collaborative agreement with Suzhou Ribo Life Science for the development and commercialization of RNA-targeted therapeutics in China in April 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Akcea Therapeutics’ Volanesorsen Performed in 2Q17

    Ionis Pharmaceuticals’ (IONS) Volanesorsen is a drug designed to reduce apoC-III protein production and lower triglycerides for patients with dyslipidemia.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Ionis Reports Revenue Growth in 2Q17

    Ionis (IONS) is a biopharmaceutical company that develops and commercializes RNA-targeted therapies.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What’s Ionis Pharmaceuticals’ Valuation?

    Ionis Pharmaceuticals (IONS) has been one of the leading pharmaceutical companies in the RNA-targeted therapeutic space for over 26 years.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Why Jazz Is Expected to Report a Robust Revenue Growth Rate

    On August 3, JAZZ managed to secure regulatory approval from the FDA for its innovative drug, Vyxeos, as a treatment option for two types of acute myeloid leukemia.

    By Margaret Patrick
  • uploads///Analysts Recommendations
    Company & Industry Overviews

    What Analysts Recommend for BioMarin Pharmaceuticals

    A total of 20 analysts were analyzing BioMarin Pharmaceuticals in July 2017. Six analysts recommended a “strong buy,” while nine analysts suggested a “buy.”

    By Daniel Collins
  • uploads///Analysts Ratings
    Company & Industry Overviews

    What Analysts Recommend for United Therapeutics in June 2017

    Thirteen analysts covered United Therapeutics in June 2017. Two analysts recommended a “strong buy.”

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Developments for Ionis Pharmaceuticals after 1Q17

    Ionis’s recent developments As discussed earlier, Ionis Pharmaceuticals (IONS) is focused on the development of drugs for the treatment of diseases with limited or no therapeutic options. Corporate developments In April 2017, Ionis entered into a collaborative agreement with Suzhou Ribo Life Science for the development and commercialization of RNA[1.ribonucleic acid]-targeted therapeutics in China. In […]

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Akcea Therapeutics’ Volanesorsen: 1Q17 Performance

    Volanesorsen Ionis Pharmaceuticals’s (IONS) volanesorsen is a drug designed to reduce apolipoprotein C-III production and triglycerides in patients with dyslipidemia. Akcea Therapeutics, a wholly owned subsidiary of Ionis, is engaged in pre-commercialization activities for volanesorsen, and will take care of the drug’s commercialization once it is approved by the FDA and the European Commission. The […]

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Understanding Ionis Phamaceuticals’ Revenue Stream in 1Q17

    Ionis Phamaceuticals’ revenue Ionis Pharmaceuticals (IONS) reported revenue of $110.3 million in 1Q17, 200% higher than its revenue of $36.9 million in 1Q16. Analysts estimate that its revenue will increase by over 100% to $78.9 million in 2Q17, mainly driven by growth in research and development revenue. Revenue performance The above graph shows Ionis’s revenue over the […]

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Changes in Ionis Pharmaceuticals’ Valuation after 1Q17

    In 1Q17, Ionis Pharmaceuticals reported EPS (earnings per share) of $0.03 on revenue of $110.3 million, compared with EPS of -$0.52 on revenue of $36.9 million in 1Q16. In this series, we’ll look at its valuation since 1Q17.

    By Mike Benson
  • uploads///Chart  Developments
    Earnings Report

    Novartis’s 1Q17 Earnings: Recent Developments

    On January 6, 2017, Novartis announced the collaborative agreement with Ionis Pharmaceuticals (IONS) and its subsidiary Akcea Therapeutics.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Valuation Compared to Its Peers

    According to March 20, 2017, data, Ionis stock has risen 4.1% over the last 12 months.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Alnylam Pharmaceuticals’s Therapies to Treat hATTR Amyloidosis

    The European Medicines Agency (or EMA) has approved tafamidis for stage 1 hATTR amyloidosis.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Novartis’s Recent Developments

    Novartis (NVS) reported flat revenues at constant exchange rates during 4Q16 as well as in fiscal 2016. This was driven by growth in Sandoz revenues.

    By Mike Benson
  • Company & Industry Overviews

    Why Is the ClearBridge Aggressive Growth Fund Lagging behind Peers?

    SHRAX has been a below average YTD performer. The past year until October 14 was hard on the fund. It placed dead last among the 12 peers in this review.

    By David Ashworth
  • uploads///Chart
    Company & Industry Overviews

    How Ionis Pharmaceuticals’ Valuation Compares to Its Peers

    Ionis’s stock value has fallen 42% over the last 12 months. Analysts estimate that the stock has the potential to return ~27% over the next 12 months.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    ALNY Should Complete Revusiran’s Endeavour Trial Enrollment in Late 2016

    If the Endeavour study results in positive data, Alnylam Pharmaceuticals may become a major rare disease player like its peers United Therapeutics (UTHR) and Vertex Pharmaceuticals.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    ALNY Reports Positive Results from Patisiran’s Open Label Extension Study

    On July 1, 2016, Alnylam Pharmaceuticals (ALNY) published positive preliminary results from its ongoing Phase 2 open label extension study.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Inside Neurocrine Biosciences’ Analyst Recommendations in 2016

    Based on the recommendations of eight brokerage firms, a Bloomberg survey reported that 100% of analysts gave Neurocrine Biosciences “buy” recommendations.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    What’s Ionis Pharmaceuticals Doing with IONIS-TTR?

    In March 2010, Ionis entered into a preferred partner alliance with GlaxoSmithKline (GSK) for the development and commercialization of IONIS-TTR.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at Ionis Pharmaceuticals’ Nusinersen

    Ionis Pharmaceuticals (IONS) has entered into a collaborative agreement with Biogen Idec (BIIB) for the development and commercialization of nusinersen.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Understanding Ionis Pharmaceuticals’ 2015 Revenue Stream

    Ionis Pharmaceuticals (IONS) reported revenues of $284 million in 2015. Analysts are estimating that revenues will decline more than 16% to $237 million in 2016.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Analyst Estimates for Ionis Pharmaceuticals’ 2016 Revenue

    Analyst estimates show Ionis Pharmaceuticals’ 2016 revenue at $237 million. That’s a decline of more than 16% compared to $284 million for 2015.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Ionis Pharmaceuticals: Valuation Compared to Its Peers

    In this series, we’ll be looking at Ionis Pharmaceuticals’ (IONS) products and other factors that drive its revenues. This will give us a better understanding of what drives Ionis’s revenues.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Neurocrine Biosciences’ Valbenazine Launch: What You Need to Know

    Neurocrine Biosciences (NBIX) expects to submit a new drug application to the FDA for Valbenazine in 2016.

    By Margaret Patrick
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.